{"id":"NCT00849381","sponsor":"GlaxoSmithKline","briefTitle":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand","officialTitle":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female Brazilian, Taiwanese and Thai Subjects Who Had Received Control Vaccine in Study 580299/008","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2009-02-23","resultsPosted":"2014-08-25","lastUpdate":"2014-09-12"},"enrollment":1239,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"GSK580299, GSK Biological's HPV vaccine","otherNames":["CervarixTM"]}],"arms":[{"label":"Cervarix Compliance Issue Centre Group","type":"EXPERIMENTAL"},{"label":"Cervarix All Centres Group","type":"EXPERIMENTAL"}],"summary":"This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).","primaryOutcome":{"measure":"Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)","timeFrame":"During the entire study period (up to Month 12)","effectByArm":[{"arm":"Cervarix Group","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"26 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":9,"countries":["Brazil","Taiwan","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":1237},"commonTop":[]}}